

REMARKS

The Examiner divided the claims into three groups: Group 1 (Claims 21-22) drawn to a method of preventing footrot; Group 2 (Claims 23-32) drawn to a method for producing a whole cell culture vaccine; and Group 3 (Claims 33-35) drawn to a vaccine. The Examiner requested that Applicants elect a group for examination.

Applicants hereby elects, without traverse, Group 1, Claims 21-22, directed to a method of preventing footrot. Applicants are requesting the cancellation of Claims 23-35 without prejudice to pursue those claims in another application.

Applicants also are requesting that Claim 21 be amended prior to examination. Applicants would like to remove the word "intramuscularly" and limit the dosage of the vaccine from about 1 ml to about 2 ml. Support for this dosage of vaccine is found on pages 5, 10, and 12 (Example 1) of the Specification. No new matter is being added.

Any questions or issues can be directed to the below signed attorney at this address. Thank you for your assistance with this matter.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7922


David L. Marks
Attorney for Applicants
Reg. No. 37,881

Date: January 12, 2005